KC-764

• Description :

  KC-764 is an orally active, reversible cyclooxygenase inhibitor with relative selectivity for platelet cyclooxygenase. KC-764 inhibits platelet thromboxane A2 (TXA2) production and platelet aggregation, with IC50s of 0.23 μM and 26 nM, respectively. KC-764 can be used for the research on antiplatelet and recurrence prevention in ischemic stroke[1].

• UNSPSC :

  12352005

• Target :

  Prostaglandin Receptor

• Related Pathways :

  GPCR/G Protein

• Field of Research :

  Neurological Disease

• Smiles :

  O=C(C1=C2C=CC=CN2N=C1C)C3=CNCCC3

• Molecular Formula :

  C14H15N3O

• Molecular Weight :

  241.29

• References & Citations :

  [1]Satoh K, et al. Pyrazolopyridine derivative acts as a novel cyclooxygenase inhibitor: antiplatelet effect in aged patients with ischemic stroke. J Am Geriatr Soc. 1994 Jun;42 (6) :639-42.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  TXA2/TP

• CAS Number :

  [94457-09-7]